Neither T-helper type 2 nor Foxp3(+) regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity

Oral atorvastatin has prevented or reversed paralysis in the multiple sclerosis (MS) model experimental autoimmune encephalomyelitis (EAE), and reduced development of new MS lesions in clinical trials. Besides inhibiting development of encephalitogenic T cells, atorvastatin treatment of EAE has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Martin S, Prod’homme, Thomas, Youssef, Sawsan, Dunn, Shannon E, Steinman, Lawrence, Zamvil, Scott S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922392/
https://www.ncbi.nlm.nih.gov/pubmed/24498870
http://dx.doi.org/10.1186/1742-2094-11-29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922392/
https://www.ncbi.nlm.nih.gov/pubmed/24498870
http://dx.doi.org/10.1186/1742-2094-11-29

Ejemplares similares